E

EyePoint Pharmaceuticals
D

EYPT

6.17500
USD
-0.19
(-2.91%)
مغلق
حجم التداول
16,269
الربح لكل سهم
-2
العائد الربحي
-
P/E
-3
حجم السوق
421,450,116
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    B
    BTAI
    -0.22000
    (-9.36%)
    2.13000 USD
    E
    EVOK
    -0.21000
    (-4.02%)
    5.02000 USD
    F
    FULC
    -0.00500
    (-0.13%)
    3.85000 USD
    H
    HOTH
    -0.02000
    (-1.85%)
    1.06000 USD
    المزيد
الأخبار
المقالات

العنوان: EyePoint Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.